Truist Lifts Nurix Therapeutics Price Target to $32 on Roche Deal
Truist raises NRIX target after Roche secures exclusive rights to blood cancer drug in $2.3 billion partnership. Truist analyst Gregory Renza increased Nurix Therapeutics Inc. (NASDAQ:NRIX) price target to $32 from $30, maintaining a Buy rating. The adjustment follows a $2